Close Menu


Pressure, Pressure

According to the New York Times, scientists are concerned about political pressure on the race for a COVID-19 vaccine.

According to NPR, there were irregularities in how the contract to collect COVID-19 data was awarded to TeleTracking Technologies.

The tube, cap, and multitube consumables enable SARS-CoV-2 tests on its automated Panther and Panther Fusion sample-to-answer molecular diagnostic systems.

Along with the federal settlement, the company will also pay an additional $13.2 million to settle civil claims by different state attorneys general.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

Rick Bright, the former BARDA director, updates his whistleblower complaint to include allegations of ongoing retaliation, CBS News reports.

In Phase 2 pilots, four healthcare organizations helped HL7 refine its FHIR Genomics specification but  uncovered many remaining hurdles to true interoperability.

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

The New York Times reports that a federal watchdog group has recommended Rick Bright be reinstated to his former post during its investigation of his whistleblower claims.

The Washington Post reports former BARDA Director Rick Bright alleges in a whistleblower complaint he was removed from his post for trying to "prioritize science and safety over political expediency."


New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.